Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 26

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1
Chunk 26
---
 portfolio has been tailored to reflect our efforts to harness the adaptive immune system for research, diagnostic and therapeutic applications. Our patent claims extend to not only adaptive immune receptor molecules, but also to uniquely powerful techniques for sequencing immune cell receptors, determining clonality and immune competency, diagnosing disease, predicting responses to immunotherapy and identifying new drug candidates. Our granted patent protection generally expires in years ranging from 2029 to 2040. 

Critical know-how we develop is protected by a trade secrecy program to ensure against inappropriate disclosure or use. Encompassed in our know-how is our proprietary database of coding sequences, antigen reactivities and safety profiles for immune receptors, which is vast and growing. Even with collaborators, access to our immune medicine platform technology is limited and tightly controlled through contracts and careful communication. We own our immune medicine platform, including improvements we or collaborators make to it, and retain rights in data resulting from its use. 

We also pursue trademark registration for our product and service names and promotional slogans in our existing and projected markets. 

Intellectual Property Portfolio by the Numbers 

As of December 31, 2024, our intellectual property portfolio consisted of the following:

•847 patent applications filed worldwide directly or in conjunction with a co-owner or licensor since 2009; 

•70 pending patent applications;

•416 issued and allowed patents across our immune medicine platform, including more than 151 patents related to diagnostic approaches in lymphoid malignancies; 

•24 patent families directed to methods and tools useful in our immune medicine platform for non-target specific immunosequencing and research; 

•17 patent families directed to methods and tools useful in diagnosis, prognosis and disease monitoring, including clonoSEQ, certain diagnostic methods and TCR-antigen binding; 

•12 patent families directed to methods and tools useful in drug discovery, including our drug discovery screening processes, MIRA and pairSEQ; 

•1 patent family directed to SARS-CoV-2 vaccines;

•11 patent families directed to novel antigen targets and immune medicine-based therapeutic modalities; 

•4 patent families directed to gene sequencing technology; and 

•28 trademarks registered and pending registration worldwide. 

Patent Portfolio 

We have developed an expansive patent portfolio in commercially important markets with claims to critical aspects of our technology, beginning with our first patent applications exclusively licensed from Fred Hutchinson Cancer Research Center (“Fred Hutch”) in 2009. Our ongoing patent strategy is to generate a return on our patenting investments, which values substantive quality over volume to build a defensible